^
    over4years
    [VIRTUAL] Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 (ENDO-I 2020)
    All subjects received Sandostatin® (100μg immediate release; SIR) by deep SC injection 24h before MTD201... MTD201 (30mg) by either IM or SC injection produced continuous octreotide release over a period of at least 63 days at levels predicted to maintain efficacious plasma concentrations at steady state with a dosing interval of up to 8 weeks. Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
    Clinical • PK/PD data • Late-breaking abstract
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Octreosphere (octreotide extended release) • adecatumumab (MT201) • octreotide acetate • octreotide acetate solution for injection • octreotide sustained release (MTD201)
    over4years
    Extended Release Octreotide Pharmacokinetics in Healthy Subjects After Subcutaneous Injection of MTD201 (ENDO 2020)
    MTD201 (30mg) by either IM or SC injection produced continuous octreotide release over a period of at least 63 days at levels predicted to maintain efficacious plasma concentrations at steady state with a dosing interval of up to 8 weeks. Reduced plasma IGF-1 concentrations were maintained throughout the study period. Unlike marketed octreotide depot products, MTD201 can be simply and rapidly reconstituted in WFI to give a stable suspension injectable via 21G needle in a 1.5mL volume.
    Clinical • PK/PD data • Late-breaking abstract
    |
    IGF1 (Insulin-like growth factor 1)
    |
    Octreosphere (octreotide extended release) • adecatumumab (MT201) • octreotide acetate • octreotide sustained release (MTD201)